Quick Takeaways
- Sandra Milligan has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value: $940,049.
- Recent insider filing activity is available below.
Follow Filing Activity
Follow Sandra Milligan and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original Filing| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| OGN | Organon & Co. | Head of Research & Development | $723,042 | 04 May 2023 | ||
| GOSS | Gossamer Bio, Inc. | Director | $111,456 | +$50,016 | +81% | 19 Aug 2025 |
| AWHL | Aspira Women's Health Inc. | Interim CEO | $105,551 | 31 Dec 2024 | ||
| SYRE | Spyre Therapeutics, Inc. | Director | 29 May 2025 |
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|